NCT06132828

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

A Multicenter, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 216 (estimated)
• Sponsor: Zhejiang Doer Biologics Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors

Detailed description

This study is an open, phase I study to evaluate the safety, tolerability, pharmacokinetics of DR30206 in patients with advanced or metastatic solid tumors. The study is composed of two parts: part A is Dose escalation stage and part B is Dose expansion stage

Conditions

• Solid Tumor

Interventions

Type	Name	Description
DRUG	DR30206	Subjects receive DR30206 intravenously

Timeline

• Start date: 2023-11-27
• Primary completion: 2026-03-30
• Completion: 2026-07-30
• First posted: 2023-11-15
• Last updated: 2025-07-03

Locations

1 site across 1 country: China